^
CANCER:

Endocrine Cancer

Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
No biomarker
Adrenal Cortex Carcinoma
mitotane
Sensitive
:
A1
No biomarker
Adrenal Cortex Carcinoma
cisplatin + carboplatin + etoposide IV + mitotane + SGN-15
Sensitive
:
A2
No biomarker
Adrenal Cortex Carcinoma
pembrolizumab
Sensitive
:
A2
No biomarker
Adrenal Cortex Carcinoma
cisplatin
Sensitive
:
A2
No biomarker
Adrenal Cortex Carcinoma
cisplatin + etoposide IV
Sensitive
:
A2
No biomarker
Adrenal Cortex Carcinoma
cisplatin + doxorubicin hydrochloride + etoposide IV + mitotane
Sensitive
:
A2
No biomarker
Adrenal Cortex Carcinoma
carboplatin + etoposide IV + mitotane
Sensitive
:
A2
No biomarker
Adrenal Cortex Carcinoma
carboplatin + doxorubicin hydrochloride + etoposide IV
Sensitive
:
A2
No biomarker
Adrenal Cortex Carcinoma
carboplatin + etoposide IV
Sensitive
:
A2
No biomarker
Adrenal Cortex Carcinoma
carboplatin + doxorubicin hydrochloride + etoposide IV + mitotane
Sensitive
:
A2
No biomarker
Adrenal Cortex Carcinoma
cisplatin + etoposide IV + mitotane
Sensitive
:
A2
No biomarker
Adrenal Cortex Carcinoma
cisplatin + doxorubicin hydrochloride + etoposide IV
Sensitive
:
A2
No biomarker
Adrenal Cortex Carcinoma
streptozocin
Sensitive
:
A2
No biomarker
Adrenal Cortex Carcinoma
mitotane + streptozocin
Sensitive
:
A2
MSI-H/dMMR
Adrenal Cortex Carcinoma
pembrolizumab
Sensitive
:
C1
RRM1 underexpression
Adrenal Cortex Carcinoma
mitotane
Sensitive
:
C3
TMB-L
Adrenal Cortex Carcinoma
mitotane
Sensitive
:
C3
MGMT underexpression
Pituitary Gland Carcinoma
temozolomide
Sensitive
:
C3
TMB-L + PD-L1 underexpression
Pituitary Gland Carcinoma
nivolumab + ipilimumab
Sensitive
:
C3
MSH2 mutation
Adrenal Cortex Carcinoma
pembrolizumab
Sensitive
:
C4
SDHB mutation
Pituitary Gland Carcinoma
temozolomide
Sensitive
:
C4
MSH2 mutation + MSH6 mutation
Pituitary Gland Carcinoma
pembrolizumab
Sensitive
:
C4
STK11 mutation
Pituitary Gland Carcinoma
temozolomide + capecitabine
Resistant
:
C4
STK11 mutation
Pituitary Gland Carcinoma
everolimus
Sensitive
:
C4
ATRX mutation + TP53 mutation + PTEN mutation
Pituitary Gland Carcinoma
temozolomide
Sensitive
:
C4
TMB-H
Pituitary Gland Carcinoma
nivolumab + ipilimumab
Resistant
:
C4
TMB-H
Pituitary Gland Carcinoma
temozolomide
Resistant
:
C4
MSH2 deletion + MSH6 deletion
Pituitary Gland Carcinoma
temozolomide
Resistant
:
C4
FGFR3-TACC3 fusion
Adrenal Cortex Carcinoma
erdafitinib
Sensitive
:
C4
TOP2A overexpression
Adrenal Cortex Carcinoma
rubitecan
Sensitive
:
D
TOP2A overexpression
Adrenal Cortex Carcinoma
teniposide
Sensitive
:
D
CDK1 overexpression
Adrenal Cortex Carcinoma
DSP-2033
Sensitive
:
D